<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00105521</url>
  </required_header>
  <id_info>
    <org_study_id>EMR 62225-019</org_study_id>
    <nct_id>NCT00105521</nct_id>
  </id_info>
  <brief_title>Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMD Serono</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to test multiple doses of sarizotan to establish a dose with
      maximal safety and efficacy for treating treatment associated dyskinesia in Parkinson's
      disease participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 30, 2004</start_date>
  <completion_date type="Actual">March 31, 2006</completion_date>
  <primary_completion_date type="Actual">March 31, 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Diary-Based On-Time Without Dyskinesia at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>On-time without dyskinesia was defined as a period (in hours) when the participant had no symptoms of off-time and was not asleep; also, participant had no difficulty in performing voluntary movements (that is, without dyskinesia). Off-time was defined as a period (in hours) when participant experienced increased parkinsonian symptoms (e.g. immobility or inability to move with ease). On-time was recorded by participant in a participant diary.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Modified Abnormal Involuntary Movement Scale (AIMS) Score at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Modified AIMS was a 7-item investigator-assessed scale to assess severity of dyskinesia. Each item was rated on a 0 (none) to 4 (severe) scale. Modified AIMS score was sum of the all item scores and ranged from 0 to 28, where higher score indicated increased severity. Modified AIMS score in resting state as well as with activity is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Items 32 and 33 Composite Score at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The UPDRS was an investigator-assessed rating tool to follow the longitudinal course of Parkinson's disease. Items 32 and 33 assessed duration of dyskinesia and disability due to dyskinesia, respectively. Both items were rated on a 0 to 4-point scale, where higher scores indicated higher duration of dyskinesia and more disability due to dyskinesia, respectively. The Items 32 and 33 composite score was sum of the individual item scores and ranged from 0 to 8, where higher score indicated more complications due to dyskinesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in UPDRS Part III Total Score at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The UPDRS was an investigator-assessed rating tool to follow the longitudinal course of Parkinson's disease. UPDRS Part III total score was the sum of the 27 answers (rated on 0 to 4-point scale) related to motor examination, and ranged from 0-108. Higher scores indicated worse motor function. Change from baseline in UPDRS Part III total score, assessed during on-time (time when the participant has no parkinsonian symptoms) as well as off-time (time when the patient experiences increased parkinsonian symptoms), is reported.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">398</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Dyskinesia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo matched to sarizotan tablet orally twice daily up to Week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarizotan 2 milligrams per day (mg/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive sarizotan 2 milligrams (mg) per day (given in 2 divided daily doses) up to Week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarizotan 4 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive sarizotan 4 mg/day (given in 2 divided daily doses) up to Week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarizotan 10 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive sarizotan 10 mg/day (given in 2 divided daily doses) up to Week 12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sarizotan</intervention_name>
    <description>Sarizotan will be administered twice daily.</description>
    <arm_group_label>Sarizotan 2 milligrams per day (mg/day)</arm_group_label>
    <arm_group_label>Sarizotan 4 mg/day</arm_group_label>
    <arm_group_label>Sarizotan 10 mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching to sarizotan will be administered twice daily.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The participant is an out-patient

          -  The participant presents with a diagnosis of idiopathic Parkinson's disease

          -  Prior therapy with all registered Parkinsonian medication is allowed

        Exclusion Criteria:

          -  (For female participants) The participant is pregnant or lactating

          -  The participant is participating in another clinical study or has done so within the
             past 30 days

          -  The participant has received neurosurgical intervention related to Parkinson's disease

          -  The participant has relevant renal impairment

          -  The participant has relevant hepatic impairment

          -  The participant is suffering from any dementia or psychiatric illness

          -  The participant has a history of allergic asthma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>EMD Serono Inc., an affiliate of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>372703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <zip>60194</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118-2526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Golden Valley</city>
        <state>Minnesota</state>
        <zip>55427</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614-5811</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Upland</city>
        <state>Pennsylvania</state>
        <zip>19013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Goetz CG, Damier P, Hicking C, Laska E, Müller T, Olanow CW, Rascol O, Russ H. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord. 2007 Jan 15;22(2):179-86.</citation>
    <PMID>17094088</PMID>
  </reference>
  <reference>
    <citation>Goetz CG, Laska E, Hicking C, Damier P, Müller T, Nutt J, Warren Olanow C, Rascol O, Russ H. Placebo influences on dyskinesia in Parkinson's disease. Mov Disord. 2008 Apr 15;23(5):700-7. doi: 10.1002/mds.21897.</citation>
    <PMID>18175337</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2005</study_first_submitted>
  <study_first_submitted_qc>March 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2005</study_first_posted>
  <results_first_submitted>September 4, 2017</results_first_submitted>
  <results_first_submitted_qc>September 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 2, 2018</results_first_posted>
  <last_update_submitted>September 4, 2017</last_update_submitted>
  <last_update_submitted_qc>September 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's Disease</keyword>
  <keyword>Dyskinesia</keyword>
  <keyword>Dyskinesia associated with dopaminergic treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received placebo matched to sarizotan tablet orally twice daily up to Week 12.</description>
        </group>
        <group group_id="P2">
          <title>Sarizotan 2 mg/Day</title>
          <description>Participants received sarizotan 2 milligrams per day (mg/day) (given in 2 divided daily doses) up to Week 12.</description>
        </group>
        <group group_id="P3">
          <title>Sarizotan 4 mg/Day</title>
          <description>Participants received sarizotan 4 mg/day (given in 2 divided daily doses) up to Week 12.</description>
        </group>
        <group group_id="P4">
          <title>Sarizotan 10 mg/Day</title>
          <description>Participants received sarizotan 10 mg/day (given in 2 divided daily doses) up to Week 12.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="97"/>
                <participants group_id="P4" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="90"/>
                <participants group_id="P3" count="80"/>
                <participants group_id="P4" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received placebo matched to sarizotan tablet orally twice daily up to Week 12.</description>
        </group>
        <group group_id="B2">
          <title>Sarizotan 2 mg/Day</title>
          <description>Participants received sarizotan 2 mg/day (given in 2 divided daily doses) up to Week 12.</description>
        </group>
        <group group_id="B3">
          <title>Sarizotan 4 mg/Day</title>
          <description>Participants received sarizotan 4 mg/day (given in 2 divided daily doses) up to Week 12.</description>
        </group>
        <group group_id="B4">
          <title>Sarizotan 10 mg/Day</title>
          <description>Participants received sarizotan 10 mg/day (given in 2 divided daily doses) up to Week 12.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="98"/>
            <count group_id="B2" value="101"/>
            <count group_id="B3" value="97"/>
            <count group_id="B4" value="102"/>
            <count group_id="B5" value="398"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.1" spread="8.3"/>
                    <measurement group_id="B2" value="63.4" spread="9.2"/>
                    <measurement group_id="B3" value="63.2" spread="9.7"/>
                    <measurement group_id="B4" value="62.9" spread="8.7"/>
                    <measurement group_id="B5" value="63.2" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="177"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Diary-Based On-Time Without Dyskinesia at Week 12</title>
        <description>On-time without dyskinesia was defined as a period (in hours) when the participant had no symptoms of off-time and was not asleep; also, participant had no difficulty in performing voluntary movements (that is, without dyskinesia). Off-time was defined as a period (in hours) when participant experienced increased parkinsonian symptoms (e.g. immobility or inability to move with ease). On-time was recorded by participant in a participant diary.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Modified intent-to-treat (ITT) population included all randomized participants who received at least one treatment dose and who had at least one follow-up visit assessment for an efficacy target outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to sarizotan tablet orally twice daily up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>Sarizotan 2 mg/Day</title>
            <description>Participants received sarizotan 2 mg/day (given in 2 divided daily doses) up to Week 12.</description>
          </group>
          <group group_id="O3">
            <title>Sarizotan 4 mg/Day</title>
            <description>Participants received sarizotan 4 mg/day (given in 2 divided daily doses) up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>Sarizotan 10 mg/Day</title>
            <description>Participants received sarizotan 10 mg/day (given in 2 divided daily doses) up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diary-Based On-Time Without Dyskinesia at Week 12</title>
          <description>On-time without dyskinesia was defined as a period (in hours) when the participant had no symptoms of off-time and was not asleep; also, participant had no difficulty in performing voluntary movements (that is, without dyskinesia). Off-time was defined as a period (in hours) when participant experienced increased parkinsonian symptoms (e.g. immobility or inability to move with ease). On-time was recorded by participant in a participant diary.</description>
          <population>Modified intent-to-treat (ITT) population included all randomized participants who received at least one treatment dose and who had at least one follow-up visit assessment for an efficacy target outcome.</population>
          <units>hours/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="3.3"/>
                    <measurement group_id="O2" value="1.9" spread="3.8"/>
                    <measurement group_id="O3" value="1.7" spread="3.0"/>
                    <measurement group_id="O4" value="1.8" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Modified Abnormal Involuntary Movement Scale (AIMS) Score at Week 12</title>
        <description>Modified AIMS was a 7-item investigator-assessed scale to assess severity of dyskinesia. Each item was rated on a 0 (none) to 4 (severe) scale. Modified AIMS score was sum of the all item scores and ranged from 0 to 28, where higher score indicated increased severity. Modified AIMS score in resting state as well as with activity is reported.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Modified ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to sarizotan tablet orally twice daily up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>Sarizotan 2 mg/Day</title>
            <description>Participants received sarizotan 2 mg/day (given in 2 divided daily doses) up to Week 12.</description>
          </group>
          <group group_id="O3">
            <title>Sarizotan 4 mg/Day</title>
            <description>Participants received sarizotan 4 mg/day (given in 2 divided daily doses) up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>Sarizotan 10 mg/Day</title>
            <description>Participants received sarizotan 10 mg/day (given in 2 divided daily doses) up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Modified Abnormal Involuntary Movement Scale (AIMS) Score at Week 12</title>
          <description>Modified AIMS was a 7-item investigator-assessed scale to assess severity of dyskinesia. Each item was rated on a 0 (none) to 4 (severe) scale. Modified AIMS score was sum of the all item scores and ranged from 0 to 28, where higher score indicated increased severity. Modified AIMS score in resting state as well as with activity is reported.</description>
          <population>Modified ITT population.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 12: Modified AIMS at Rest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="5.7"/>
                    <measurement group_id="O2" value="-3.0" spread="5.3"/>
                    <measurement group_id="O3" value="-2.7" spread="4.1"/>
                    <measurement group_id="O4" value="-3.7" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12: Modified AIMS with Activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="5.9"/>
                    <measurement group_id="O2" value="-3.3" spread="5.6"/>
                    <measurement group_id="O3" value="-3.0" spread="4.8"/>
                    <measurement group_id="O4" value="-3.6" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Unified Parkinson’s Disease Rating Scale (UPDRS) Items 32 and 33 Composite Score at Week 12</title>
        <description>The UPDRS was an investigator-assessed rating tool to follow the longitudinal course of Parkinson’s disease. Items 32 and 33 assessed duration of dyskinesia and disability due to dyskinesia, respectively. Both items were rated on a 0 to 4-point scale, where higher scores indicated higher duration of dyskinesia and more disability due to dyskinesia, respectively. The Items 32 and 33 composite score was sum of the individual item scores and ranged from 0 to 8, where higher score indicated more complications due to dyskinesia.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Modified ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to sarizotan tablet orally twice daily up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>Sarizotan 2 mg/Day</title>
            <description>Participants received sarizotan 2 mg/day (given in 2 divided daily doses) up to Week 12.</description>
          </group>
          <group group_id="O3">
            <title>Sarizotan 4 mg/Day</title>
            <description>Participants received sarizotan 4 mg/day (given in 2 divided daily doses) up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>Sarizotan 10 mg/Day</title>
            <description>Participants received sarizotan 10 mg/day (given in 2 divided daily doses) up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Unified Parkinson’s Disease Rating Scale (UPDRS) Items 32 and 33 Composite Score at Week 12</title>
          <description>The UPDRS was an investigator-assessed rating tool to follow the longitudinal course of Parkinson’s disease. Items 32 and 33 assessed duration of dyskinesia and disability due to dyskinesia, respectively. Both items were rated on a 0 to 4-point scale, where higher scores indicated higher duration of dyskinesia and more disability due to dyskinesia, respectively. The Items 32 and 33 composite score was sum of the individual item scores and ranged from 0 to 8, where higher score indicated more complications due to dyskinesia.</description>
          <population>Modified ITT population.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="1.4"/>
                    <measurement group_id="O2" value="-1.4" spread="1.6"/>
                    <measurement group_id="O3" value="-1.1" spread="1.4"/>
                    <measurement group_id="O4" value="-1.3" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in UPDRS Part III Total Score at Week 12</title>
        <description>The UPDRS was an investigator-assessed rating tool to follow the longitudinal course of Parkinson’s disease. UPDRS Part III total score was the sum of the 27 answers (rated on 0 to 4-point scale) related to motor examination, and ranged from 0-108. Higher scores indicated worse motor function. Change from baseline in UPDRS Part III total score, assessed during on-time (time when the participant has no parkinsonian symptoms) as well as off-time (time when the patient experiences increased parkinsonian symptoms), is reported.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>modified ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo matched to sarizotan tablet orally twice daily up to Week 12.</description>
          </group>
          <group group_id="O2">
            <title>Sarizotan 2 mg/Day</title>
            <description>Participants received sarizotan 2 mg/day (given in 2 divided daily doses) up to Week 12.</description>
          </group>
          <group group_id="O3">
            <title>Sarizotan 4 mg/Day</title>
            <description>Participants received sarizotan 4 mg/day (given in 2 divided daily doses) up to Week 12.</description>
          </group>
          <group group_id="O4">
            <title>Sarizotan 10 mg/Day</title>
            <description>Participants received sarizotan 10 mg/day (given in 2 divided daily doses) up to Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in UPDRS Part III Total Score at Week 12</title>
          <description>The UPDRS was an investigator-assessed rating tool to follow the longitudinal course of Parkinson’s disease. UPDRS Part III total score was the sum of the 27 answers (rated on 0 to 4-point scale) related to motor examination, and ranged from 0-108. Higher scores indicated worse motor function. Change from baseline in UPDRS Part III total score, assessed during on-time (time when the participant has no parkinsonian symptoms) as well as off-time (time when the patient experiences increased parkinsonian symptoms), is reported.</description>
          <population>modified ITT population.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 12: UPDRS Part III On-Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="6.8"/>
                    <measurement group_id="O2" value="-0.1" spread="6.4"/>
                    <measurement group_id="O3" value="-0.1" spread="6.8"/>
                    <measurement group_id="O4" value="-0.8" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12: UPDRS Part III Off-Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="8.7"/>
                    <measurement group_id="O2" value="-1.1" spread="8.7"/>
                    <measurement group_id="O3" value="-0.0" spread="7.6"/>
                    <measurement group_id="O4" value="-1.8" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Among serious adverse events (SAEs), only data for total # affected by any SAE is available. Due diligence was done and all potential information sources have been exhausted; no further information could be retrieved. Hence, for SAEs the preferred term is reported as “Not Available” and System Organ Class as “General Disorders”.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received placebo matched to sarizotan tablet orally twice daily up to Week 12.</description>
        </group>
        <group group_id="E2">
          <title>Sarizotan 2 mg/Day</title>
          <description>Participants received sarizotan 2 mg/day (given in 2 divided daily doses) up to Week 12.</description>
        </group>
        <group group_id="E3">
          <title>Sarizotan 4 mg/Day</title>
          <description>Participants received sarizotan 4 mg/day (given in 2 divided daily doses) up to Week 12.</description>
        </group>
        <group group_id="E4">
          <title>Sarizotan 10 mg/Day</title>
          <description>Participants received sarizotan 10 mg/day (given in 2 divided daily doses) up to Week 12.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>No Coding Applied</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Not Available</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>No Coding Applied</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="85" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Falls</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine protein kinase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dyskinesia aggravated</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Tremor aggravated</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Parkinsonism aggravated</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>For SAEs, due diligence was done and all potential information sources have been exhausted, no further information could be retrieved apart from what is currently reported.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Merck KGaA Communication Center,</name_or_title>
      <organization>Merck Serono, a division of Merck KGaA</organization>
      <phone>496151725200</phone>
      <email>service@merckgroup.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

